| abstract |
Disclosed is the use of a monoclonal antibody that specifically binds a TRAIL receptor DR5, wherein said antibody, in its soluble form, has in vivo and in vitro apoptosis-inducing activity in target cells expressing DR5, for preparation of a medicament for selectively inducing apoptosis in said target cells, wherein said medicament is formulated for administration along with one or more therapeutic agents, wherein if the therapeutic agent is a chemotherapeutic agent, the chemotherapeutic agent is selected from the group consisting of leflunomide, dactinomycin, tamoxifen, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, 6-thioguanine, carmustine, BCNU, lomustine, CCNU, cytosine, araboside, estramustine, hydroxyurea, procarbazine, bulsulfan, medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methylestosteraone, diethylstilbestrol diphosphate, chlorotrianisene, testolactone, mephalen, chorambucil, mechlorethamine, thiotepa, bethamethasone sodium phosphate, dicarbazine, asparaginase, mitotane, vincristine sulphate and vinblastine sulphate. (62) (62) Divided Out of 533164 |